In this special edition of PharmaVentures Insights, Dr Fintan Walton, CEO & Founder of PharmaVentures, leads a panel discussion to address whether a dual fundraising and partnering strategy is the best way forward for an emerging biotech.
Panelists include Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist Search and Evaluation at Novo Nordisk, Jeanne Bolger, Vice President, Venture Investments at Johnson & Johnson Innovation, Bart Dzikowski, Managing Director, Head of Transactions & Legal at Novartis Venture Fund, Tim Luker, Senior Director, External Innovation, Global External R&D at Eli Lilly and Company, and Kevin Johnson, Co-Founder at Medicxi.
Special Edition: A Combined Fundraising & Partnering Strategy – a Better Way to Secure Success?
In this exclusive interview, Fintan Walton, CEO of PharmaVentures, speaks with Marc Funk, the new CEO of Recipharm.
Recipharm is a leading Swedish CDMO, founded in 1995, which has expanded to over 30 sites across 10 countries which are mainly in Europe, but also in Israel, India, and North America. The company’s successful inorganic growth has been largely through the build and buy model of its founders, according to Marc.
They discuss the company’s current situation and how Marc plans to take it forward, including:
The takeover of Recipharm by EQT, a global investment organisation with a “passion for future-proofing companies”
Focus on operational excellence, meeting the needs unmet by the competition, emerging technologies, and innovation
Opportunities in the areas of small molecules, biologics, and North America
Recipharm’s and EQT’s “priority 1” – customer focus
Affordable and safe drugs
How Recipharm are operating during the COVID-19 pandemic
What Marc sees as his biggest challenges, both now and in the future
Watch: Contract Manufacturing in the Pharmaceutical Industry: Recipharm
Can Partnering Conference Cancellations Affect Dealmaking in 2020?
We all got used to the partnering conference circuit as a means to introduce the latest developments to potential partners. So now they are all temporarily suspended whilst we overcome the current global health challenge, how do you make sure your opportunities are still getting in front of your potential partners. PharmaVentures has been successfully connecting buyers and sellers for over 28 years with and without partnering conferences. PharmaVentures’ CEO, Dr. Fintan Walton talks about how PharmaVentures is continuing a business as usual approach for all of our clients.
In this special edition of PharmaVentures Insights, we explore the challenges faced by pharmaceutical companies during the manufacturing divestment process, and how to accelerate the divestment process to achieve a successful outcome.
Paul Larsmon spoke with leading experts including:
Mark Bamforth, President and CEO, Arranta Bio
Stéphane Lepeu, Directeur Général Délégué / Chief Commercial Officer, DELPHARM
The Chief Executive of PharmaVentures, a leading global corporate advisory firm in healthcare licensing, M&A and fundraising discusses how the current pandemic of 2020 will define the winners and losers in biopharmaceuticals.
What are the most important things to think about when doing a licensing deal with Western big pharma? How do you engage with them and keep the momentum going? Can language become a barrier in doing a deal? How is the Korean biopharmaceutical sector viewed by those of the West? Join Adrian Dawkes, Managing Director and Summer Park, Business Development Director for an exclusive discussion on doing deals with big pharma.